Timber Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TMBR research report →
About the company
Timber Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the research, development, and market introduction of treatments for rare dermatological conditions. The company's key product candidates include: TMB-001, a patented topical isotretinoin formulation, which has successfully completed Phase 2b clinical trials.
- CEO
- John Koconis
- IPO
- 2014
- Employees
- 9
- HQ
- Basking Ridge, NJ, US
Price Chart
- Market Cap
- $1.18M
- P/E
- -0.04
- P/S
- 14.14
- P/B
- 0.14
- EV/EBITDA
- 0.40
- Div Yield
- 0.00%
- Gross Margin
- -15892.35%
- Op Margin
- -23125.86%
- Net Margin
- -23299.05%
- ROE
- -209.49%
- ROIC
- -345.61%
- Revenue
- $83.18K · -71.87%
- Net Income
- $-19,379,450 · -82.15%
- EPS
- $-9.19 · 30.11%
- Op Income
- $-19,235,396
- FCF YoY
- -69.97%
- 52W High
- $3.39
- 52W Low
- $0.32
- 50D MA
- $2.45
- 200D MA
- $2.12
- Beta
- -0.65
- Avg Volume
- 107.90K
Get TickerSpark's AI analysis on TMBR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 20, 23 | Koconis John | other | 70,385 |
| Aug 20, 23 | Mendelsohn Alan | other | 35,193 |
| Aug 20, 23 | Lucchese Joseph | other | 35,193 |
| Apr 15, 23 | Koconis John | other | 45,010 |
| Apr 15, 23 | Gaal Lubor | other | 4,100 |
| Apr 15, 23 | Gaal Lubor | other | 4,100 |
| Apr 15, 23 | Mendelsohn Alan | other | 22,505 |
| Apr 15, 23 | Pirozzi Gianluca | other | 4,100 |
| Apr 15, 23 | Pirozzi Gianluca | other | 4,100 |
| Apr 15, 23 | Sitar Edward J | other | 5,327 |
Our TMBR coverage
Recent articles, reports, and earnings notes.
No research on TMBR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TMBR report →Similar companies
Peers in the same neighborhood.